Skip to main content
AutoimmunityB CellsCAR T Cell TherapyImmunotherapyLupusPersonalized MedicineT Cells

Ep. 31: “Autoimmune Diseases and B Cell Immunity” Featuring Dr. Mark Shlomchik

By June 21, 2022January 9th, 2023No Comments

Mark Shlomchik


Dr. Mark Shlomchik is UPMC Endowed Distinguished Professor and Chair of the Department of Immunology at the University of Pittsburgh. He is also a Founder and Chief Scientific Officer of BlueSphere Bio, a company working to create individualized T cell therapies for the treatment of cancer. Dr. Shlomchik’s lab focuses on systemic autoimmune diseases, long-lived B cell immunity, and immunopathogenesis. He talks about the role of toll-like receptors in lupus, how his autoimmune disease research led to potential cancer therapies, and starting a biotech company with his brother.

Featured Products and Resources:

The Immunology Science Round Up

Antibody Escape in Omicron Subvariants – Researchers showed that the BA.4 and BA.5 SARS-CoV-2 sub-lineages contain mutations that reduce neutralization from vaccines and previous infection.

Long COVID in the Brain – After mild respiratory COVID, mice displayed elevated CSF cytokines, impaired hippocampal neurogenesis, decreased oligodendrocytes, and myelin loss.

Pregnancy and Intracellular Infection – Pregnancy-induced post-translational antibody modification enables protection against the prototypical intracellular pathogen Listeria monocytogenes.

Sex-Specific Immune Responses to Tumors – Scientists demonstrated that sex-related differences in tumor burden depend on adaptive immunity.

Image courtesy of Dr. Mark Shlomchik

Subscribe to our newsletter!

Never miss updates about new episodes.